Bausch Health Responds to Market Rumors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Jefferies on Bausch Health Companies (BHC): 'Another Case of Irresponsible Journalism Wreaks Havoc in Shares'
July 24, 2024 3:43 PM EDTJefferies analyst Glen Santangelo reiterated a Buy rating and $13.00 price target on Bausch Health Companies (NYSE: BHC)
The analyst comments "This morning, a report from Reorg comments that BHC was negotiating a pre-packaged Chap 11 bankruptcy filing. BHC has since commented this is NOT true. This reminds us of the April Wall St Journal article that insinuated that one of Zoetiss drugs (Librela) was killing dogs! Both situations were unfounded. Unfortunately,... More
